Scritto da Administrator vg59srl il . Pubblicato in Documento Intersocietario SIPREC.

Aspetti epidemiologici e ruolo protettivo della vaccinazione antinfluenzale in pazienti con malattie cardiovascolari

  • Bibliografia:
    1. “Influenza (Seasonal).” World Health Organization (WHO), 3 October 2023, https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed 30 June 2024.
    2. “Factsheet about seasonal influenza.” European Centre for Disease Prevention and Control, 12 April 2022, https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet. Accessed 30 June 2024.
    3. Circolare 20 maggio 2024 “Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2024-2025”.“Influenza, pubblicata la Circolare con le raccomandazioni per la stagione 2024-2025.”” Ministero della Salute, 21 May 2024, https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=6567. Accessed 30 June 2024.
    4. Maleki F, Welch V, Lopez SMC, et al. Understanding the Global Burden of Influenza in Adults Aged 18-64 years: A Systematic Literature Review from 2012 to 2022. Adv Ther. 2023;40(10):4166-4188. doi:10.1007/s12325-023-02610-1
    5. “Seasonal influenza.” European Centre for Disease Prevention and Control, https://www.ecdc.europa.eu/en/seasonal-influenza. Accessed 30 June 2024
    6. Fattore G, Pongiglione B, Vezzosi L. Excess hospitalizations and in-hospital mortality associated with seasonal influenza in Italy: a 11-year retrospective study. BMC Infect Dis. 2024;24(1):227. Published 2024 Feb 20. doi:10.1186/s12879-024-09071-z
    7. https://www.trovanorme.salute.gov.it/norme/dettaglioAtto.spring?id=95963&page=newsett. Accessed 30 June 2024.
    8. “Estimated Flu Illnesses, Medical Visits, and Hospitalizations Prevented by Vaccination in the United States — 2019–2020 Flu Season.” CDC, 29 December 2023, https://www.cdc.gov/flu/about/burden-prevented/2019-2020.htm. Accessed 18 June 2024
    9. Vaccinazioni per gruppi di popolazione: gruppi a rischio.” Epicentro.iss.it, https://www.epicentro.iss.it/vaccini/GruppiRischio. Accessed 30 June 2024.
    10. Ma J, Mena M, Mandania RA, et al. Associations between Combined Influenza and Pneumococcal Pneumonia Vaccination and Cardiovascular Outcomes. Cardiology. 2021;146(6):772-780. doi:10.1159/000519469
    11. “Studies Suggest Influenza Infection Raises Risk of Heart Attack.” CDC, 16 February 2024, https://www.cdc.gov/flu/spotlights/2023-2024/flu-heart-study.htm. Accessed 30 June 2024
    12. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345-353. doi:10.1056/NEJMoa1702090
    13. Chow EJ, Rolfes MA, O'Halloran A, et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study. Ann Intern Med. 2020;173(8):605-613. doi:10.7326/M20-1509
    14. Roth GA, Mensah GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action. J Am Coll Cardiol. 2020;76(25):2980–1.
    15. Sethi NJ, Safi S, Korang SK, et al. Antibiotics for secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2021;2(2):CD003610. Published 2021 Feb 23. doi:10.1002/14651858.CD003610.pub4
    16. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711-1720. doi:10.1001/jama.2013.279206
    17. Yedlapati SH, Khan SU, Talluri S, et al. Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2021;10(6):e019636. doi:10.1161/JAHA.120.019636
    18. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation [published correction appears in Circulation. 2015 Apr 14;131(15):e408. doi: 10.1161/CIR.0b013e3182a77a15]. Circulation. 2011;124(22):2458-2473. doi:10.1161/CIR.0b013e318235eb4d
    19. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106
    20. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
    21. Modin D, Jørgensen ME, Gislason G, et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139(5):575-586. doi:10.1161/CIRCULATIONAHA.118.036788
    22. Vardeny O, Claggett B, Udell JA, et al. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016;4(2):152-158. doi:10.1016/j.jchf.2015.10.012

Roberta Siliquini

Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)
Dipartimento di Scienze della Sanità Pubblica e Pediatria Università di Torino

Leggi tutto …Aspetti epidemiologici e ruolo protettivo della vaccinazione antinfluenzale in pazienti con...

  • Visite: 1622

Scritto da Administrator vg59srl il . Pubblicato in Documento Intersocietario SIPREC.

Impatto dell’influenza sulle malattie cardiovascolari: basi fisiopatologiche e manifestazioni cliniche

  • Bibliografia:
    1. Volpe M, Battistoni A. What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season? Eur Heart J Suppl. 2023 Feb 14;25(Suppl A):A1-A4.
    2. Carro A. The impact of influenza vaccination on cardiovascular diseases. Eur Heart J Suppl 2023 Feb 14;25(Suppl A):A25-A30.
    3. Skaarup KG, Modin D, Nielsen L, Jensen JUS, Biering-Sørensen T. Influenza and cardiovascular disease pathophysiology: strings attached. Eur Heart J Suppl. 2023 Feb 14;25(Suppl A):A5-A11.
    4. Antonelli Incalzi R, Consoli A, Lopalco P, Maggi S, Sesti G, Veronese N, Volpe M. Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion. Intern Emerg Med. 2024 Apr;19(3):619-640.
    5. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T et al. Acute myocardial infarction after laboratory- confirmed influenza infection. N Engl J Med 2018;378:345–353.
    6. de Boer AR, Riezebos-Brilman A, van Hout D, van Mourik MSM, Rümke LW, de Hoog MLA, Vaartjes I, Bruijning-Verhagen PCJL. Influenza infection and Acute Myocardial Infarction. NEJM Evid. 2024 Jul;3(7):EVIDoa2300361
    7. Liu R, Liu X, Yang P, Du X, He L, Chen T et al. Influenza-associated cardiovascular mortality in older adults in Beijing, China: a population- based time-series study. BMJ Open 2020;10:e042487.
    8. Fagnoul D, Pasquier P, Bodson L, Ortiz JA, Vincent J-L, De Backer D. Myocardial dysfunction during H1N1 influenza infection. J Crit Care 2013;28:321–327.
    9. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez P et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009;13: R201.
    10. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10: 83–92.
    11. Yap FH, Ho PL, Lam KF, Chan PK, Cheng YH, Peiris JS. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol 2004;73:617–623.
    12. Diaz-Arocutipa C, Saucedo-Chinchay J, Mamas MA, Vicent L. Influenza vaccine improves cardiovascular outcomes in patients with coronary artery disease: a systematic review and meta-analysis. Travel Med Infect Dis 2022;47:102311.
    13. Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan M. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc 2021;10:e019636.
    14. Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B et al. Influenza vaccine in heart failure cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation 2019;139:575–586.
    15. Battistoni A, Gallo G, Aragona CO, Barchiesi F, Basolo A, Bellone S et al. [Prevention Italy 2021—an update of the 2018 consensus document and recommendations for the prevention of cardiovascular disease in Italy]. G Ital Cardiol (Rome) 2021;22:1–105.
    16. Panhwar MS, Kalra A, Gupta T, Kolte D, Khera S, Bhatt D et al. Relation of concomitant heart failure to outcomes in patients hospitalized with influenza. Am J Cardiol 2019;123:1478–1480.
    17. Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol 1981;113:30–43.
    18. Chow EJ, Rolfes MA, O’Halloran A, Anderson EJ, Bennett NM, Billing L et al. Acute cardiovascular events associated with influenza in hospitalized adults. Ann Intern Med 2020;173:605–613.
    19. Guan X, Yang W, Sun X, Wang L, Ma B, Li H et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflamm Res 2012;61:591–598.
    20. Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis associated with influenza A H1N1pdm2009. Influenza Res Treat 2012;2012:351979.
    21. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J 2018; 51:1701794.
    22. Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J et al. Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study. JAMA Cardiol 2019;4:363–369.
    23. Pizzini A, Burkert F, Theurl I, Weiss G, Bellmann-Weiler R. Prognostic impact of high sensitive Troponin T in patients with influenza virus infection: a retrospective analysis. Heart Lung 2020;49:105–109.
    24. Harris JE, Shah PJ, Korimilli V, Win H. Frequency of troponin elevations in patients with influenza infection during the 2017–2018 influenza season. Int J Cardiol Heart Vasc 2019;22:145–147.
    25. Kodama M. Influenza myocarditis. Circ J 2010;74:2060–2061.
    26. Haidari M, Wyde PR, Litovsky S, Vela D, Ali M, Casscells SW et al. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis 2010;208:90–96.
    27. Naghavi M, Wyde P, Litovsky S, Madjid M, Akhtar A, Naguib S et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003;107:762–768.
    28. Witzleb W, Witzleb H, Mehlhorn J, Sprössig M, Wutzler P. Demonstration of influenza virus A in human heart by semiquantitative virus assay and immunofluorescence. Acta Virol 1976;20:168.
    29. Visseren FL, Bouwman JJ, Bouter KP, Diepersloot RJ, de Groot PH, Erkelens DW. Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost 2000;84:319–324.
    30. Kreutz RP, Bliden KP, Tantry US, Gurbel PA. Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. J Thromb Haemost 2005;3:2108–2109.
    31. Li J, Zhang H, Zhang C. Role of inflammation in the regulation of coronary blood flow in ischemia and reperfusion: mechanisms and therapeutic implications. J Mol Cell Cardiol 2012;52:865–872.
    32. Gopal R, Marinelli MA, Alcorn JF. Immune mechanisms in cardiovascular diseases associated with viral infection. Front Immunol 2020;11: 570681.
    33. Uchmanowicz I, Łoboz-Rudnicka M, Szeląg P, Jankowska-Polańska B, Łoboz-Grudzień K. Frailty in heart failure. Curr Heart Fail Rep 2014; 11:266–273.

Massimo Volpe

Dipartimento di Medicina Clinica e Molecolare, Università di Roma Sapienza
IRCCS San Raffaele, Roma
Società Italiana per la Prevenzione Cardiovascolare (SIPREC)

Leggi tutto …Impatto dell’influenza sulle malattie cardiovascolari: basi fisiopatologiche e manifestazioni...

  • Visite: 1050

Scritto da Administrator vg59srl il . Pubblicato in Documento Intersocietario SIPREC.

La vaccinazione antinfluenzale: impatto sullo sviluppo di eventi cardiovascolari. Aspetti epidemiologici e studi clinici

  • Bibliografia:
    1. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU vaccination acute coronary syndromes (FLUVACS) study. Circulation 2002; 105:2143–2147.
    2. Gurfinkel EP, de la Fuente R L, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 2004; 25:25–31.
    3. Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU vaccination acute coronary syndromes (FLUVACS) registry. Tex Heart Inst J 2004; 31:28–32.
    4. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29:1350–1358.
    5. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011;32: 1730–1735.
    6. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310:1711–1720.
    7. IAMI Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR et al. Influenza vaccination after myocardial infarction. Circulation 2021;144: 1476–1484.
    8. María Inés Sosa-Liprandi, Ezequiel José Zaidel, Álvaro Sosa-Liprandi, A recent experience on the role of influenza vaccination on cardiovascular events, European Heart Journal Supplements, 2023. 25:A31–A35
    9. Modin D, Lassen MCH, Claggett B, Johansen ND, Keshtkar-Jahromi M, Skaarup KG, et al. Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis. Eur J Heart Fail. 2023; 25:1685–1692
    10. Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc 2021; 10:e019636.
    11. Fonseca HAR, Furtado RHM, Zimerman A, Lemos PA, Franken M, Monfardini F et al. Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial. Eur Heart J 2022; 43:4378–4388.
    12. Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart 2020; 106: 350–357.
    13. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. Eur Heart J 2017; 38:326–333.
    14. Loeb M, Dokainish H, Dans A, Palileo-Villanueva LM, Roy A, Karaye K et al. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): rationale and design. Am Heart J 2019; 212:36–44
    15. Volpe M, Battistoni A, What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season? European Heart Journal Supplements, European Heart Journal Supplements, 2023, 25: A1–A4
    16. Weinberger, B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 2021;18:38
    17. Addario A, Célarier T, Bongue B, Barth N, Gavazzi G, Botelho-Nevers E. Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review. Geroscience. 2023; 45:3419-3447
    18. Wang C-S, Wang S-T, Chou P. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine. 2002;20:2494–2499.
    19. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322–1332
    20. Liu I-F, et al. Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: a nationwide population-based study. Prev Med. 2012; 54:431–433.
    21. Hung M-C, Lu P-J, Srivastav A, Cheng YJ, Williams WW. Influenza vaccination coverage among adults with diabetes, United States, 2007–08 through 2017–18 seasons. Vaccine 2020; 38:6545–6552.
    22. Modin D, Claggett B, Kober L, Schou M, Jensen JUS, Solomon SC et al. Influenza vaccination is associated with reduced cardiovascular mortality in adults with diabetes. A nationwide cohort study. Diabetes Care 2020; 43:2226–2233.
    23. Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A et al. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. CMAJ 2016;188: E342–E351.
    24. Jassen MCH, Johansen ND, Modin D, Nealon J, Samson S, Dufournet M, Loiacono MM, Larsen CS, Jensen AMR, Landler NE, Claggett BL, Solomon SD, Landray MJ, Gislason GH, Køber L, Jensen JUS, Sivapalan P, Vestergaard LS, Krause TG, Biering-Sørensen T. Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial. Diabetes Obes Metab. 2024; 26:1821-1829.
    25. Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos1, Alessandro Biffi2 3, José-Manuel Boavida 4, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H Franco, Sigrun Halvorsen, F D Richard Hobbs 5, Monika Hollander, Ewa A Jankowska, Matthias Michal 6, Simona Sacco 7, Naveed Sattar, Lale Tokgozoglu 8, Serena Tonstad, Konstantinos P Tsioufis 9, Ineke van Dis 10, Isabelle C van Gelder, Christoph Wanner 11, Bryan Williams; ESC National Cardiac Societies; ESC Scientific Document Grou 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337.

Allegra Battistoni

Dipartimento di Medicina Clinica e Molecolare, Università di Roma Sapienza
Società Italiana per la Prevenzione Cardiovascolare (SIPREC)

Leggi tutto …La vaccinazione antinfluenzale: impatto sullo sviluppo di eventi cardiovascolari. Aspetti...

  • Visite: 293

Scritto da Administrator vg59srl il . Pubblicato in Documento Intersocietario SIPREC.

La vaccinazione antinfluenzale nei pazienti ad alto rischio

  • Bibliografia:
    1. Eichner, M., Schwehm, M., Eichner, L. et al. Direct and indirect effects of influenza vaccination. BMC Infect Dis 2017; 17: 308.
    2. Presidenza del Consiglio dei Ministri Conferenza permanente per i rapporti tra lo stato le regioni e le province autonome. Intesa Governo, Regioni e Province autonome di Trento e di Bolzano sul “Piano nazionale di prevenzione vaccinale (PNPV) 2023 -2025” e sul “Calendario nazionale vaccinale”. Intesa 02 agosto 2023, n.193. G.U. Serie Generale, n. 194 del 21 agosto 2023. su: https://www.trovanorme.salute.gov.it/norme/dettaglioAtto.spring?id=95963&page=newsett
    3. Società Italiana Malattie Infettive e Tropicali (SIMIT), Società Italiana Igiene, Medicina Preventiva e Sanità Pubblica (SItI). Proposte operative per la vaccinazione dei soggetti adulti fragili/immunocompromessi. 15 Novembre 2022. su: https://www.igienistionline.it/archivio/2022/20.htm
    4. Vaccines against influenza: WHO position paper-May2022. Wkly Epidemiol Rec 2022; 19:185-208
    5. Ministero della Salute. Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2024-2025. Circolare 0014845-20/05/2024-DGPRE-DGPRE-P. su: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2024&codLeg=100738&parte=1%20&serie=null
    6. European Centre for Disease Prevention and Control. Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory confirmed influenza in individuals aged 18 years and over. Stockholm: ECDC; 2024. su: https://www.ecdc.europa.eu/sites/default/files/documents/Systematic-review-update-enhanced-seasonal%20flu-vaccines.pdf
    7. Antonelli Incalzi R, Consoli A, Lopalco P, et al. Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion. Intern Emerg Med. 2024;19:619-40.
    8. Dicembrini I, Silverii GA, Clerico A, et al. Influenza: Diabetes as a risk factor for severe related-outcomes and the effectiveness of vaccination in diabetic population. A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2023; 33:1099-110.
    9. Mohr A, Plentz A, Sieroslawski A, et al. Use of Pneumococcal and influenza vaccine in patients with COPD, asthma bronchiale and interstitial lung diseases in south east Germany. Respir Med. 2020; 174:106207.
    10. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2024 report). su: https://goldcopd.org/2024-gold-report/
    11. Härmälä S, Parisinos C, Shallcross L, O'Brien A, Hayward A. Effectiveness of pneumococcal and influenza vaccines to prevent serious health complications in adults with chronic liver disease: a protocol for a systematic review. BMJ Open. 2018; 8:e018223.
    12. Shrestha AB, Mohammed YA, Umar TP, et al.. Exploring the possible therapeutic role of influenza vaccine in chronic kidney disease patients. Ann Med Surg 2023; 85:642-4.
    13. Omidi F, Zangiabadian M, Shahidi Bonjar AH, Nasiri MJ, Sarmastzadeh T. Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies. Sci Rep. 2023; 13:20235
    14. Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: Evaluation of the safety profile. Hum Vaccin Immunother. 2018; 14:657-70.
    15. Arrazola Martínez MP, Eiros Bouza JM, Plans Rubió P, et al. Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the population aged 65 or over. Rev Esp Quimioter. 2023; 36:334-45.
    16. Puig-Barbera J, Diez-Domingo J, Belenguer Varea A, et al. Effectiveness of MF59-adjuvanted subunit vaccine in preventing hospitalizations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007; 25:7313-21
    17. Lapi F, Marconi E, Simonetti M, et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalization for pneumonia and cerebro/cardiovascular events in elderly. Exp Rev Vaccines 2019. Doi: 10.1080/14760584.2019.1622418
    18. Van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study. Vaccine 2020; 38:372-9
    19. Pelton SI, Divino V, Shah D, et al. Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017-2018 influenza season. Vaccines 2020; 8:446
    20. Vardeny O, Kim K, Udell JA, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical Trial. 2021; 325:39-49.
    21. Pelton SI, Divino V, Postma MJ, et al. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season. 2021; 39:2396-407.
    22. Levin MJ, Divino V, Shah D, et al. Comparing the clinical and economic outcomes associated with adjuvanted versus high-dose trivalent influenza vaccine among adults aged ≥ 65 years in the us during the 2019-20 influenza season-a retrospective cohort analysis. Vaccines 2021; 9:1146.
    23. Johansen ND, Modin D, Nealon J, et al. A pragmatic randomized feasibility trial of influenza vaccines. NEJM Evid. 2023; 2:EVIDoa2200206.
    24. Johansen ND, Modin D, Skaarup KG, et al. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial. Clin Microbiol Infect. 2024; S1198-743X(24)00039-9.
    25. Imran M, Puig-Barbera J, Oertiz JR, et al. Relative effectiveness of the cell-based quadrivalent influenza vaccine in preventing cardiorespiratory hospitalizations in adults aged 18-64 years during the 2019-2020 US influenza season. Open Forum Infect Dis. 2023; 10:ofad304
    26. Imran M, Puig-Barbera J, Ortiz JR, et al. Relative effectiveness of the MF59®-adjuvanted influenza vaccine versus high-dose and non-adjuvanted influenza vaccines in preventing cardiorespiratory hospitalizations during the 2019-2020 us influenza season. Influenza Other Respir Viruses. 2024; 18(4):e13288.
    27. Palmu AA, Pepin S, Syrjänen RK, et al. High-dose quadrivalent influenza vaccine for prevention of cardiovascular and respiratory hospitalizations in older adults. influenza Other Respir Viruses. 2024; 18:e13270.

Giovanni Gabutti

Coordinatore GdL “Vaccini e Politiche Vaccinali”, Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)

Leggi tutto …La vaccinazione antinfluenzale nei pazienti ad alto rischio

  • Visite: 2080

Scritto da Administrator vg59srl il . Pubblicato in Documento Intersocietario SIPREC.

Appropriatezza vaccinale per i pazienti a rischio cardiovascolare aumentato, anche in relazione all’età

  • Bibliografia:
    1. Circolare n.0014845-20/05/2024-DGPRE-DGPRE-P “Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2024-2025”.
    2. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season.February 23, 2024. Available at: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2024-2025/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season.pdf?sfvrsn=2e9d2194_7&download=true.
    3. Bartolozzi. Vaccini e Vaccinazioni, Terza edizione. Elsevier Editore, 2012.
    4. Del Giudice G ,Hilbert A k, Bugarini R, Minutello A, Popova O, Toneatto D et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24: 3063–3065.
    5. Lapi F, Marconi E, Simonetti M, Baldo V, Rossi A, Sessa A, Cricelli C. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines. 2019; 18: 663-670.
    6. Pebody R, Whitaker H, Zhao H, Andrews N, Ellis J, Donati M, Zambon M. Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19. Vaccine 2020; 38: 173-179.
    7. Pebody RG, Whitaker H, Ellis J, Andrews N, Marques DFP, Cottrell S et al. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. Vaccine. 2020; 38: 489-497.
    8. Bellino S, Piovesan C, Bella A, Rizzo C, Pezzotti P, Ramigni M. Determinants of vaccination uptake, and influenza vaccine effectiveness in preventing deaths and hospital admissions in the elderly population; Treviso, Italy, 2014/2015-2016/2017 seasons. Hum Vaccin Immunother 2020; 16 :301-312.
    9. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W et al. Relative effectiveness of influenza vaccines among the U.S. elderly, 2018-19. J Infect Dis. 2020 Feb 26. pii: jiaa080. doi: 10.1093/infdis/jiaa080.
    10. Domnich A, Panatto D, Pariani E, Napoli C, Chironna M, Manini et al. Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults. nt J Infect Dis. 2022 Dec;125:164-169. doi: 10.1016/j.ijid.2022.10.041. Epub 2022 Nov 2. PMID: 36332902
    11. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45. doi: 10.1056/NEJMoa1315727. PMID: 25119609.
    12. Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018 May;17(5):435-443. doi: 10.1080/14760584.2018.1471989. Epub 2018 May 16. PMID: 29715054.
    1. Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine X. 2023 Jun 5;14:100327. doi: 10.1016/j.jvacx.2023.100327. PMID: 37333054; PMCID: PMC10276206
    2. Li APY, Cohen CA, Leung NHL, Fang VJ, Gangappa S, Sambhara S, Levine MZ, Iuliano AD, Perera RAPM, Ip DKM, Peiris JSM, Thompson MG, Cowling BJ, Valkenburg SA. Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults. NPJ Vaccines. 2021 Feb 16;6(1):25. doi: 10.1038/s41541-021-00289-5. PMID: 33594050.].
    3. Stein AN et al. Superior Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines Against Outpatient Test-Confirmed Influenza Over Three Consecutive Seasons in the United States. Presented at ESWI, Valencia 2023.

Paolo Bonanni

Dipartimento di Scienze della Salute – Università degli Studi di Firenze
Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)

Leggi tutto …Appropriatezza vaccinale per i pazienti a rischio cardiovascolare aumentato, anche in relazione...

  • Visite: 1322

Scritto da Administrator vg59srl il . Pubblicato in Documento Intersocietario SIPREC.

Strategia ed organizzazione della vaccinazione anti-influenzale sul territorio: il ruolo del Medico di Medicina Generale

Giulio Nati1,2, Giovanni Gabutti3

1 Membro Gruppo di Lavoro Regionale Strategie Vaccinali- Regione Lazio
2 Società Italiana per la Prevenzione Cardiovascolare (SIPREC)
3 Coordinatore GdL “Vaccini e Politiche Vaccinali”, Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)

Leggi tutto …Strategia ed organizzazione della vaccinazione anti-influenzale sul territorio: il ruolo del...

  • Visite: 803

Rimani connesso con SIPREC

Per rimanere sempre aggiornato su progetti di tipo formativo, news e tematiche che riguardano la prevenzione cardiovascolare.

Siprec Logo
SIPREC
Iscrizione

Sei laureato in materie medico-scientifiche e discipline attinenti la Prevenzione Cardiovascolare? Diventa Socio SIPREC.

Iscriviti
Richiesta di patrocinio

Scopri come ottenere il patrocinio SIPREC per iniziative ritenute meritevoli.

Richiedi patrocinio
Sede

SIPREC Società Italiana per la Prevenzione Cardiovascolare

Viale Maresciallo Pilsudski, 118
00197 Roma
Tel. +39 06 8543541

Codice Fiscale: 97250070584
Partita IVA: 08584021003
segreteria@siprec.it

Contattaci

© 2022 S.I.PRE.C. Società italiana per la prevenzione cardiovascolare - P.I. 08584021003

Cookie Policy - Privacy Policy -